Usefulness of $^{68}$Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia

Dong Yun Lee\(^1\), Seung Hun Lee\(^2\), Beom-Jun Kim\(^3\), Wanlim Kim\(^3\), Pil Whan Yoon\(^3\), Sang Ju Lee\(^1\), Seung Jun Oh\(^1\), Jung-Min Koh\(^2\) & Jin-Sook Ryu\(^{1,2,\ast}\)

Tumor-induced osteomalacia (TIO) is an uncommon paraneoplastic syndrome presenting with sustained hypophosphatemia. Treatment of choice is removal of the tumor causing the TIO, but identification of the culprit tumor by routine imaging is challenging. This study aimed to assess the usefulness of somatostatin receptor imaging, called $^{68}$Ga-DOTATOC PET/CT, in the management of patients with TIO. Twelve patients who were suspected of having TIO underwent $^{68}$Ga-DOTATOC PET/CT. Lesion detectability and maximum standardized uptake value ($\text{SUV}_{\text{max}}$) were determined and retrospectively compared with the clinical/imaging surveillance and histopathologic diagnosis. The median duration of suspected TIO with hypophosphatemia was 7.8 years (range 2.1–21.0). Conventional radiologic and/or nuclear medicine images failed to identify the culprit tumors. However, $^{68}$Ga-DOTATOC PET/CT scans showed that 8 of the 12 patients had positive lesions, suggesting the presence of focal culprit tumors. The $\text{SUV}_{\text{max}}$ of positive tumors was 1.9–45.7 (median: 11.5). Six skeletal lesions and two extra-skeletal lesions were identified. Seven of the lesions were pathologically confirmed as potential culprits of TIO. Hypophosphatemia was resolved in five patients who underwent lesion excision. The $^{68}$Ga-DOTATOC PET/CT is a useful whole-body imaging modality for the detection of causative tumors in patients with suspected TIO.

Tumor-induced osteomalacia (TIO), also known as oncogenic hypophosphatemic osteomalacia, is an uncommon paraneoplastic syndrome\(^1\). Up until now, less than 1000 cases of TIO were reported worldwide\(^2\)–\(^7\). The overproduction of fibroblast growth factor-23 (FGF-23) by the culprit tumors is the primary causative mechanism in TIO\(^8\). The excess circulating FGF-23 causes chronic renal phosphate wasting and decreases the enzymatic activity of 1α-hydroxylase, which leads to sustained hypophosphatemia. The majority of culprit tumors accounting for osteomalacia originate from mesenchymal tumors; therefore, their usual location is bone or soft tissue layers\(^9\). Benign phosphaturic mesenchymal tumors and hemangiopericytoma are the most common tumor in TIO, whereas malignant osteosarcoma or fibrosarcoma are very rare.

Patients with TIO have ambiguous musculoskeletal symptoms, such as long-standing weakness, myalgia, fatigue, bone pain, and even fractures. Without a physician’s astute suspicion, a long delay between the first presentation and final diagnosis of TIO is frequent due to the non-specific symptomatology and scarcity of the disease. Although TIO is a very rare disease, the suspicion of TIO and detection of the culprit tumor is essential, given the long-term debilitating morbidity associated with aberrant bone metabolism. Moreover, the treatment of choice is the complete removal or ablation of the tumor\(^10\),\(^11\). Otherwise, permanent administration of phosphate supplement would be required for patients with TIO. However, the causative tumors are difficult to localize because tumors are small and slow-growing. Upon physical examination, most culprit tumors are rarely visible or palpable. Pinpointing the exact location of the culprit tumor is also very challenging using conventional radiologic and nuclear medicine images, including magnetic resonance imaging (MRI) and $^{18}$Fluoride-Fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography/computed tomography (PET/CT)\(^12\)–\(^16\).

The discovery of somatostatin receptor (SSTR) overexpression in mesenchymal tumors\(^17\), especially type 2 SSTR, prompted specific imaging of TIO patients using $^{11}$Indium-based octreotide scans, which are classic SSTR targeting scintigraphy\(^18\). State-of-the-art PET radiotracers, such as $^{68}$Ga-labeled DOTA (\(^{68}$Ga-DOTA)-based oligopeptides (DOTA\(^2\)-Tyr\(^3\)-Octreotate, \(^{68}$Ga-DOTATATE), DOTA\(^1\)-Nal\(^3\)-octreotide, \(^{68}$Ga-DOTANOC, and DOTA\(^1\)-Phe\(^1\)-Tyr\(^4\)-octreotide \(^{68}$Ga-DOTATOC) target the SSTR in neuroendocrine tumors\(^19\). Several

---

1\(^{\text{Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.}}\)
2\(^{\text{Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.}}\)
3\(^{\text{Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.}}\)
4\(^{\text{email: jsryu2@amc.seoul.kr}}\)
recent reports demonstrated improved localization of culprit tumors in TIO using these PET radiotracers\textsuperscript{13,20,21}. Although minor changes in amino acid sequences result in a differential affinity toward the type 2 SSTR families, the three tracers have similar performances in clinical practice\textsuperscript{22}. Several reports have demonstrated the performance of \textsuperscript{68}Ga-DOTATOC PET/CT in these cohorts. In this context, we investigated the usefulness of \textsuperscript{68}Ga-DOTATOC PET/CT for the management of patients with TIO from a single Korean tertiary hospital.

**Materials and methods**

**Study design and patient selection.** The Institutional Review Board (IRB) in the Asan Medical Center (IRB no. 2019-1290) approved this study protocol and waived informed consent from patients due to the retrospective nature of the study. The study was conducted in compliance with the Declaration of Helsinki regulation. From June 2017 to May 2019, we retrospectively recruited 12 patients with suspicion of TIO who underwent \textsuperscript{68}Ga-DOTATOC PET/CT at the Asan Medical Center. Patient medical records were reviewed and documents regarding the commencement of clinical manifestations associated with TIO were retrieved. Additionally, the sequential biochemical laboratory results associated with bone metabolism and all the imaging studies, including radiology and nuclear medicine, were reviewed. When possible, we calculated the tubular reabsorption of phosphate (TRP) twice, according to the formula provided below, to evaluate the status of renal phosphate wasting\textsuperscript{23}.

\[
TRP = \left(1 - \frac{\text{serum creatinine} \times \text{urine phosphate}}{\text{urine creatinine} \times \text{serum phosphate}}\right) \times 100.
\]

\textsuperscript{68}Ga-DOTATOC PET/CT imaging. The \textsuperscript{68}Ga-DOTATOC was manually synthesized with a \textsuperscript{68}Ge/\textsuperscript{68}Ga generator (iThemba LABS, South Africa) and GMP grade DOTATOC (ABX, Germany) in the cyclotron laboratory of our institution\textsuperscript{24,25}. Quality control was performed according to European Pharmacopeia; the synthesized \textsuperscript{68}Ga-DOTATOC satisfied all quality control criteria and the radiochemical purity of the \textsuperscript{68}Ga-DOTATOC was 98.2 ± 1.0\%, as measured by HPLC. We injected a median dose of 4.65 mCi (range 3.4–5.4) \textsuperscript{68}Ga-DOTATOC, intravenously, in non-fasting patients. Sixty minutes after injection, PET/CT images were generated using the GE Discovery 690, 710, or 690 Elite systems. We acquired the emission PET scans at 3.5 min per bed. Nine patients underwent whole-body PET/CT from skull vertex to both feet. Three patients had torso PET/CT scan from the skull vertex to the proximal thigh. The lesion detectability and \textit{SUV}_{\text{max}} normalized to body weight, were determined. Additionally, we compared the \textsuperscript{68}Ga-DOTATOC PET/CT results with the outcomes of clinical/imaging surveillance and/or pathology.

**Results**

Table 1 summarizes the patient characteristics. We recruited 12 patients (four males and eight females) with a median age of 60 years (range 47–78). During the initial visit to our hospital, all patients had overt hypophosphatemia (serum phosphate ranging from 0.9 mg/dL to 2.4 mg/dL). Nine of ten patients had TRP levels below 85\%, suggesting hypophosphatemia of renal origin. We measured FGF-23 in only two patients; both patients had abnormally increased FGF-23 values that were specifically suggestive of TIO.

The median duration of suspected TIO was 7.8 years (range 2.1–21.0 years), reflecting the long-standing disease courses in most patients. During the period of suspected TIO, conventional radiologic (X-ray, CT, and MRI) and/or nuclear medicine images (bone scan and \textsuperscript{18}F-FDG PET/CT) failed to pinpoint the culprit lesions. Even though some patients demonstrated several tumors in bones or soft tissues, those tumors were considered non-specific benign primary tumors by the interpreting radiologist or nuclear medicine physician. However, 8 of the 12 patients (66.6\%) had focal positive uptake of \textsuperscript{68}Ga-DOTATOC in areas other than the physiologic uptake in the pituitary gland, adrenal glands, and uncinate process of the pancreas, thereby suggesting the possibility of culprit tumors (Fig. 1). Regarding the quantitative parameters of the eight positive tumors, \textit{SUV}_{\text{max}} ranged from 1.9 to 45.7 (median: 11.5) and the longest tumor diameter was measured between 1.1 and 6.5 cm (median 1.95 cm). Six skeletal lesions were located in the second cervical vertebral body (C2), third lumbar vertebral body, pubic bone, femur, maxilla, and fibula and two extra-skeletal lesions were located in the groin and thigh. Among the eight patients with positive tumors, seven patients (87.5\%) were pathologically confirmed and six patients finally underwent surgery to remove the tumor pinpointed by the \textsuperscript{68}Ga-DOTATOC PET/CT. Phosphate levels completely recovered in five out of six patients after the surgery without requiring phosphate supplementation. One patient with a C2 vertebral mass underwent a second \textsuperscript{68}Ga-DOTATOC PET/CT 6 months after the operation because of unresolved hypophosphatemia (Fig. 2). Compared to the basal \textsuperscript{68}Ga-DOTATOC PET/CT, the second scan showed slightly decreased but residual \textsuperscript{68}Ga-DOTATOC uptake by a persistent osteolytic lesion in the operative bed. Thus, the reason for the unresolved hypophosphatemia was a remnant tumor.

Two patients, who had focal positive uptake in \textsuperscript{68}Ga-DOTATOC PET/CT, did not undergo surgery. A 48-year-old female patient (Number 7, Fig. 3), with bone biopsy results showing a phosphaturic mesenchymal tumor on her femur, refused curative surgery because of good compliance to phosphate supplement, albeit proportionally increased phosphate demand as the mass grows. A 70-year-old male patient (Number 8) with a focal pubic bone lesion also refused to undergo biopsy or surgery, despite sustained medication. Since the patient had previous surgeries of both femurs due to prior fragility fractures, the patient was concerned about post-operative complications.

Among the four patients with negative \textsuperscript{68}Ga-DOTATOC PET/CT results, two patients seemed to have plausible clinical conditions, which excluded the possibility of TIO. One patient had a long history of the anti-viral medication, adefovir, due to chronic hepatitis B virus infection. This patient history implied an "adefovir-induced
Table 1. Patient characteristics. P phosphorous, Ca calcium, ALP alkaline phosphatase, Cr creatinine, PTH parathyroid hormone, FGF-23 fibroblast growth factor-23, TRP tubular reabsorption of phosphate, 25(OH)D 25-hydroxyvitamin D, 1,25(OH)2D 1,25-dihydroxyvitamin D, MRI magnetic resonance imaging, CT computed tomography, 18F-FDG 18Fluoride-Fluoro-deoxyglucose, PET positron emission tomography, 68Ga-DOTATOC PET/CT 68Ga-labeled DOTA0-Tyr3 octreotide (DOTATOC), FOV field of view, SUV standardized uptake value, F female, M male, W whole body, T Torso, C2 2nd cervical spine, L3 3rd lumbar spine.

| Sex | Age | Duration (years) | P (2.5–4.5 mg/dL) | Ca (8.6–10.2 mg/dL) | ALP (40–120 IU/L) | Triglyceride (140–155 mg/dL) | CR (0.7–1.4 mg/dL) | PTH (10–65 pg/mL) | FGF-23 (> 180 RU/mL) | TRP (> 85%) | 25(OH)D (8.0–51.9 ng/mL) | 1,25(OH)2D (19.6–54.3 pg/mL) | MRI/CT | 68Ga-DOTATOC PET detection (FOV) | Lesion (SUV) | Longest diameter (cm) | Pathology | Surgery | Name of surgery |
|-----|-----|-----------------|-------------------|-------------------|-----------------|-------------------------|-------------------|-------------------|------------------|----------------|------------------|------------------------|----------------|----------------|-----------------|----------------|----------------|------------------|
| 1   | F   | 74              | 21.0              | 1.6              | 8.9             | 607                      | 0.10              | 55.6             | x                | x               | 78.93            | 11.8                    | 21.8              | x                | Positive (W) | Maxilla (12.1) | 1.8            | Positive | O               | Partial maxillectomy |
| 2   | M   | 64              | 2.0              | 2.1              | 8.6             | 100                      | 0.15              | 55.3             | x                | x               | 78.92            | x                      | x                 | Positive (W) | Groin (10.4) | 11            | Positive | O               | Partial maxillection |
| 3   | F   | 71              | 12.1             | 1.4              | 8.9             | 407                      | 0.11              | 127.0            | x                | x               | 37               | 18.9                    | x                 | Positive (W) | Thigh (9.9)  | 4.5            | Positive | O               | Whole excision |
| 4   | F   | 67              | 12.2             | 1.0              | 8.2             | 325                      | 0.43              | 75.6             | x                | x               | 94.66            | 36.6                    | x                 | Positive (W) | Thigh (1.4)  | 18            | Positive | O               | Destruction of muscle |
| 5   | M   | 63              | 2.1              | 2.4              | 8.8             | 81                       | 0.17              | 61.7             | x                | x               | 83.82            | 19.6                    | x                 | Positive (W) | Thigh (1.6)  | 1.4            | Positive | O               | Partial corporeal and tibial |
| 6   | F   | 60              | 2.3              | 0.9              | 8.7             | 107                      | 0.18              | 26.6             | 622              | x               | 35.0             | 12.5                    | x                 | Positive (W) | C2 (18.7)   | 2.8            | Positive | O               | Cerebrospinal and tibial |
| 7   | F   | 64              | 10.8             | 1.1              | 8.3             | 601                      | 0.14              | 56.7             | 376               | x               | 47               | 34.4                    | x                 | Positive (W) | Thigh (12.3) | 3.2            | Positive | x               | x |
| 8   | M   | 76              | 7.3              | 2.1              | 8.6             | 406                      | 0.49              | 26.6             | 73               | x               | 34.0             | 12.0                    | x                 | Positive (W) | Thigh (12.6) | 15            | x               | x               | x |
| 9   | F   | 63              | 0.3              | 2.1              | 5.6             | 168                      | 0.12              | 28.8             | x                 | x               | 33.6             | 10.7                    | x                 | Negative (W) | x               | x               | x               | x               | x |
| 10  | F   | 63              | 9.3              | 1.8              | 7.0             | 84                       | 0.17              | 150.0            | x                 | x               | 98.7             | 17.0                    | x                 | Negative (T) | x               | x               | x               | x               | x |
| 11  | F   | 60              | 0.3              | 1.1              | 8.8             | 168                      | 0.11              | 78.1             | x                 | x               | 79.72            | 14.4                    | x                 | Negative (W) | x               | x               | x               | x               | x |
| 12  | M   | 63              | 3.9              | 1.6              | 8.5             | 103                      | 0.46              | 54.0             | 82.79            | 3.7             | 21.5             | 14.1                    | 22               | x               | Negative (T) | x               | x               | x               | x |

Figure 1. Maximum intensity projection (MIP) images and axial PET/CT images of eight patients with positive lesions according to the 68Ga-DOTATOC PET/CT. The red arrows in the MIP images indicate causative lesions in the corresponding PET/CT image, whereas the blue arrows in (B) indicate non-pathognomonic uptake. (A) Lesion in the right maxilla with SUVmax: 12.7. (B) Lesion in the right inguinal lymph node with SUVmax: 24.0. (C) Lesion in the left thigh with SUVmax: 9.9. (D) Lesion in the left fibula with SUVmax: 1.9. (E) Lesion in the L3 body with SUVmax: 4.5. (F) Lesion in the C2 body with SUVmax: 10.7. (G) Lesion in the left femur with SUVmax: 45.7. (H) Lesion in the right pubic bone with SUVmax: 12.2.
hypophosphatemic osteomalacia. Another patient had a history of celiac disease in which intestinal phosphate absorption is reduced. Concordantly, the patient’s calculated TRP value was above 85%. The remaining two patients with negative 68Ga-DOTATOC PET/CT results did not have clear reasons for persistent hypophosphatemia, and they were given phosphate supplements.

Discussion
In this study, we detected the culprit tumors that induced osteomalacia in seven out of nine patients whose calculated TRP was suggestive of renal hypophosphatemia. Five out of six patients underwent excision of the tumor identified by 68Ga-DOTATOC PET/CT and serum phosphate levels returned to normal after the surgery. In two patients, the positive lesions identified by PET/CT had elevated FGF-23 levels. Another two patients with less probability of TIO showed no evident lesions using PET/CT, and no false positive case was observed during comparisons with the biopsy results.

Although alternative radiotracers are being used for SSTR PET imaging, several investigations reported successful results in more than a dozen patients with TIO. Utilizing the same radiotracer as our study, Paquet et al. showed a 60% detection rate in 15 patients who had suspected TIO, affecting the patient management in 67% of the cases. Of note, one true positive patient without elevated FGF-23 levels was identified in the Paquet study. With 68Ga-DOTATATE, Zhang et al. showed 100% sensitivity, 90.9% specificity, and 97.7% accuracy for detecting the culprit lesions in 54 patients. Only one false positive case was detected and the ten patients with negative 68Ga-DOTATATE PET/CT were all true-negative at follow-up. However, Zhang et al. did not offer any supportive laboratory data about the level of TRP or FGF-23. Singh et al. demonstrated promising results in 17 patients using 68Ga-DOTANOC. Among the nine patients who had suspicions for culprit lesion according to the PET/CT, seven were confirmed to have those lesions. In addition, the Singh study focused on unraveling the other uptake induced by fracture or degenerative changes beyond the strength of detecting the culprit lesion. We also observed such uptake, usually induced by fracture (Blue arrows in Fig. 2B highlight the rib fractures). Those lesions exhibited a mild uptake with symmetric distributions, which contrasted with the unilateral manifestation of most of the culprit lesions. Therefore, close examination is recommended for interpretation of the 68Ga-DOTA-based PET radiotracers in patients who have concomitant fractures.

Sincere efforts have been made to reveal the culprit tumors in patients with TIO using various imaging modalities other than specific SSTR scan, including simple radiography, bone scan, CT, MRI, and 18F-FDG PET/CT. However, almost all conventional modalities showed low performance due to the non-pathognomonic findings or small tumor size. This could be the reason for inappropriately delaying the diagnosis of TIO. Indeed, we also had patients whose culprit tumors were observed on CT, MRI, or 18F-FDG PET/CT a few years before the 68Ga-DOTATOC PET/CT. However, the presence of culprit tumors was not specifically demonstrated at that time and the opportunity for early detection was lost. Figure 3 presents one such representative case.

In this context, the specificity for SSTR with “one-shot” whole-body functional imaging available by 111Indium octreotide scintigraphy is considered as a mainstay in assessing patients with TIO. However, superior spatial

---

**Figure 2.** A case of unresolved hypophosphatemia after surgical excision was demonstrated by the follow-up with 68Ga-DOTATOC PET/CT. (A) MIP image of initial 68Ga-DOTATOC PET/CT with the red arrow indicating the culprit lesion; (B) MIP image of follow-up with 68Ga-DOTATOC PET/CT 6 months after surgery with the red arrow indicating the residual culprit lesion; (C) axial PET/CT and non-enhanced CT images of culprit lesion in initial 68Ga-DOTATOC PET/CT; (D) axial PET/CT image and non-enhanced CT images of residual culprit lesion in follow-up 68Ga-DOTATOC PET/CT.
resolution inherent in the PET/CT system, better pharmacokinetics, and a higher affinity toward SSTR by shorter half-life PET radiotracers with a cyclic chelator render 68Ga-DOTA-based PET radiotracers the imaging of choice not only for patients with neuroendocrine tumors but also for patients with TIO.13,17.

The evaluation of treatment response or detection of the recurred/remnant tumor using post-treatment 18F-FDG PET/CT is a popular approach in the field of oncology.32 To the best of our knowledge, we have shown, for the first time, the additional value of follow-up with 68Ga-DOTATOC PET/CT after the basal scan to detect residual tumors whose hypophosphatemia persists even after surgery. Our results provide another option in the management of patients with TIO using 68Ga-DOTA-based PET/CT beyond the pivotal role of detecting the primary occult tumor. Previously, a case that also showed the usefulness of detecting the residual culprit tumor surgery using 68Ga-DOTANOC PET/CT was reported, but an initial PET/CT for comparison was not available.33

There are a few limitations to this study. First, even though FGF-23 is a key hormone and a sensitive indicator of TIO, testing for FGF-23 is not available in clinical practice in our country, preventing us from getting FGF-23 results. For this reason, we had just two patients who had the serum FGF-23 test. Easy accessibility to FGF-23 assays would be helpful for the early detection of TIO. Nevertheless, the results of 68Ga-DOTATOC PET/CT in this study were not affected by the results of the FGF-23 assay. Second, not all patients underwent whole-body PET/CT imaging, including that of the lower extremity, due to our inexperience. Given the positive lesion detected in the fibula of one patient, whole-body PET/CT imaging rather than torso imaging is recommended in these patients. Third, in the patients who had negative 68Ga-DOTATOC PET/CT imaging rather than torso imaging is recommended in these patients. Third, in the patients who had negative 68Ga-DOTATOC PET/CT without definite plausible reasons, we did not perform any gene mutation tests. Hypophosphatemia-related genetic diseases, such as X-linked hypophosphatemic rickets or autosomal dominant hereditary hypophosphatemic rickets,34–36, are very rare and but cannot be excluded. Finally, the total number of patients is quite low because of the rarity of the disease and limited accessibility of 68Ga-labeled radiopharmaceuticals. Due to the small number of patients included in this study, we omitted the statistical analysis regarding the diagnostic performance of 68Ga-DOTATOC PET/CT.

Figure 3. A representative case showing the specificity and strength of 68Ga-DOTATOC PET/CT as compared to conventional images. A 48-year-old woman suspected of TIO had pelvic CT and MRI 10 years before undergoing the 68Ga-DOTATOC PET/CT because of hip pain. The images showed a well-enhancing mass-like sclerotic lesion in the left femur, which was in the greater trochanter in the coronal, axial enhanced pelvic MRI (A,B) and coronal non-enhanced pelvic CT images (C). However, the lesion was considered a hematopoietic marrow or Brown tumor at that time rather than a primary bone tumor. Ten years later with 68Ga-DOTATOC PET/CT image (D), the lesion showed slowly grown tumorous features with intense radiotracer uptake strongly suggesting the culprit tumor for osteomalacia. Subsequent bone biopsy favored the presence of a phosphaturic mesenchymal tumor.
In summary, $^{68}$Ga-DOTATOC PET/CT appears to be a very robust and innovative imaging modality for detecting causative tumors in patients with suspected TIO and for detecting remnant or recurrent tumors after surgery.

Received: 7 July 2020; Accepted: 21 December 2020
Published online: 19 January 2021

References

1. de Beur, J. S. M. Tumor-induced osteomalacia. JAMA 294, 1260–1267 (2005).
2. Crossen, S. S. et al. Tumor-induced osteomalacia in a 3-year-old with an unresectable central giant cell lesion. J. Pediatr. Hematol. Oncol. 39, e21–e24 (2017).
3. Fernandez-Cooke, E. et al. Tumor-induced rickets in a child with a central giant cell granuloma: A case report. Pediatrics 135, e1518–1523 (2015).
4. Florenzano, P. et al. Tumor-induced osteomalacia. Calcif. Tissue Int. https://doi.org/10.1007/s00223-020-00691-6 (2020).
5. Jiang, Y. et al. Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J. Bone Miner. Res. 27, 1967–1975 (2012).
6. Li, X. et al. Nonresection and recurrent tumor-induced osteomalacia: A retrospective study. J. Bone Miner. Res. 35, 469–477 (2020).
7. Tella, S. H. et al. Multimodality image-guided cryosublation for inoperable tumor-induced osteomalacia. J. Bone Miner. Res. 32, 2248–2256 (2017).
8. Shimada, T. et al. Cloning and characterization of FGFR23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U.S.A. 98, 6500–6505 (2001).
9. Folpe, A. L. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity—An analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28, 1–30 (2004).
10. Mekinian, A. et al. Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia. Presse Med. 40, 309–313 (2011).
11. Sun, Z. J., Jin, J., Qiu, G. X., Gao, P. & Liu, Y. Surgical treatment of tumor-induced osteomalacia: A retrospective review of 40 cases with extreme tumors. BMC Musculoskelet. Disord. 16, 43 (2015).
12. Agrawal, K. et al. Comparison of $^{18}$F-FDG and $^{68}$Ga-DOTATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin. Nucl. Med. 40, e6–e10 (2015).
13. El-Maouche, D. El-Maouche, D. et al. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 3575–3581 (2016).
14. Fukumoto, S., Takeuchi, Y., Nagano, A. & Fujita, T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25, 375–377 (1999).
15. Shi, Z. et al. CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: A case report. Oncol. Lett. 15, 4970–4978 (2018).
16. Sood, A. et al. Bone scintigraphic patterns in patients of tumor-induced osteomalacia. Indian J. Nucl. Med. 28, 173–175 (2013).
17. Reubi, J. C., Waser, B., Laissue, J. A. & Gebbers, J. O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: In vitro identification. Cancer Res. 56, 1922–1931 (1996).
18. de Beur, S. M. J. et al. Localization of mesenchymal tumors by somatostatin receptor imaging. Lancet 359, 761–763 (2002).
19. Werner, R. A. et al. The theranostic promise for neuroendocrine tumors in the late 1990s—Where do we stand, where do we go? Theranostics 8, 6088–6100 (2018).
20. Ha, S. et al. Successful localization using (68)Ga-DOTATOC PET/CT of a phosphaturic mesenchymal tumor causing osteomalacia in a patient with concurrent follicular lymphoma. Nucl. Med. Mol. Imaging 52, 462–467 (2018).
21. Von Falck, C. et al. Ga-68-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur. J. Nucl. Med. Mol. Imaging 35, 1034–1034 (2008).
22. Virgolini, I. et al. Procedure guidelines for PET/CT tumour imaging with $^{68}$Ga-DOTA-conjugated peptides: $^{68}$Ga-DOTA-TATE, $^{68}$Ga-DOTA-NOC, $^{68}$Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging 37, 2004–2010 (2010).
23. Hong, Y. A. et al. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Clin. Exp. Nephrol. 19, 208–215 (2015).
24. de Blois, E., de Zanger, R. M. S., Oehlke, E., Chan, H. S. & Breeman, W. A. P. Semi-automated system for concentrating (68)Ga-Radiopharmaceuticals for preclinical applications. Nucl. Med. Biol. 46–55, 16–21 (2018).
25. Pfeifer-Leeg, M. et al. Synthesis and characterization of Ga-III, Y-III, and Lu-III complexes with etifenin and analogues. Z. Anorg. Allg. Chem. 642, 486–491 (2016).
26. Illei, E. A. & Econs, M. J. Approach to the hypophosphatemic patient. J. Clin. Endocrinol. Metab. 97, 696–706 (2012).
27. Paquet, M. et al. Diagnostic performance and impact on patient management of (68)Ga-DOTA-TOC-PET/CT for detecting osteomalacia-associated tumours. Eur. J. Nucl. Med. Mol. Imaging 45, 1710–1720 (2018).
28. Zhang, J. J. et al. $^{68}$Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin. Nucl. Med. 40, 642–646 (2015).
29. Singh, D. et al. Oncogenic osteomalacia: Role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br. J. Radiol. 90, 1072 (2017).
30. Rayamajhi, S. J. et al. Tumor-induced osteomalacia—Current imaging modalities and a systematic approach for tumor localization. Clin. Imaging 56, 114–123 (2019).
31. Harish, S., Jurriaans, E., Jan, E., Sur, M. & Colterjohn, N. Giant cell tumour of soft tissue causing oncogenic osteomalacia: Report demonstrating the use of octreotide scintigraphy in tumour localization. Clin. Radiol. 63, 101–107 (2008).
32. Lee, H. H. et al. Recurrence of melanoma after initial treatment: Diagnostic performance of FDG PET in posttreatment surveillance. Nucl. Med. Mol. Imaging 52, 327–333 (2018).
33. Naswa, N., Sharma, P., Kumar, R., Malhotra, A. & Bal, C. Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using Ga-68-DOTANOC PET/CT. Clin. Nucl. Med. 38, 639–640 (2013).
34. Beck-Nielsen, S. S. et al. FGFR23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis. https://doi. org/10.1186/s13023-019-1014-8 (2019).
35. Econs, M. J., McEnery, P. T., Lennon, F. & Speer, M. C. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J. Clin. Investig. 100, 2653–2657 (1997).
36. Narazaki, R. et al. Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGFR-23. Pediatr. Nephrol. 27, 861–863 (2012).
Author contributions
D.Y.L. and J.S.R. conceptualized the study and S.H.L., B.J.K., W.K., P.W.Y. and J.M.K. recruited the patients. S.J.L. and S.J.O. synthesized radiopharmaceuticals used in the study. D.Y.L. wrote the main manuscript text and prepared Figs. 1, 2 and 3. All authors finally reviewed the manuscript.

Funding
This research was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Number: HI18C2383).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to J.-S.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021